US4959462A - Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof - Google Patents

Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof Download PDF

Info

Publication number
US4959462A
US4959462A US06/823,196 US82319686A US4959462A US 4959462 A US4959462 A US 4959462A US 82319686 A US82319686 A US 82319686A US 4959462 A US4959462 A US 4959462A
Authority
US
United States
Prior art keywords
dna
rna
infection
selective hybridization
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/823,196
Inventor
Reinder Dijkema
Antonides Kos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Original Assignee
Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO filed Critical Nederlandse Organisatie voor Toegepast Natuurwetenschappelijk Onderzoek TNO
Assigned to NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK reassignment NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: DIJKEMA, REINDER, KOS, ANTONIDES
Application granted granted Critical
Publication of US4959462A publication Critical patent/US4959462A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5765—Hepatitis delta antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Definitions

  • the delta ( ⁇ ) agent is a transmissible human pathogen that superinfects individuals having type B viral hepatitis in either the acute phase or the chronic carrier state. Since its discovery by Rizetto et al, Gut 18,997-1003 (1977) no certainty as to its identity has been obtained.
  • HBV hepatitis B virus
  • ⁇ -antigen/antisystem Using immuno fluorescence, the ⁇ -antigen/antisystem has been detected and identified, revealing no immunologic relationship to the known antigen/antibody (AG/AB) systems of HBV (i.e., surface(s), core(c) and envelope(e) antigen, respectively).
  • AG/AB antigen/antibody
  • ⁇ -AG was found to be always associated with a discrete sub-population of HBsAg particles. These particles measure 35 to 37 nm in size and are composed of the ⁇ Ag and an associated low-molecular RNA encapsulated by HBsAg.
  • RNA was found to be proportionate to the relative ⁇ -Ag concentration in the serum, while a specific immuno precipitation with anti-HBsAg was found to be possible.
  • the supposed helper functions of HBV in ⁇ infection i.e., replication and encapsulation
  • the small size of the RNA have led to the hypothesis that the agent is a unique defective agent, which, for its reproduction, needs one or more HBV helper functions (for replication and expression) and that the ⁇ RNA with its subviral size only encodes the genetic information for the ⁇ antigen.
  • the suppression of circulating HBV markers (HBV/DNA) observed during the superinfection of HBV-infected chimpanzees with the ⁇ agent suggests that the agent disturbs the replication of the helper HBV.
  • the encapsulation of the ⁇ agent with HBsAg may be a different HBV helper function owing to which the agent can approach susceptible hepatocytes.
  • ⁇ -antigen associated RNA a new diagnostic agent for ⁇ antigenemia, i.e. the presence of ⁇ antigen in, for example, blood, at the RNA/DNA level, which avoids the disadvantages of existing immunological analysis for ⁇ -antigen i.e. the disturbance of the existing solid-phase radio-immunoanalysis owing to the presence of high antititers.
  • the preparatory work comprised the isolation of the ⁇ -Ag associated RNA from acute-phase serum of experimentally infected chimpanzees, molecular cloning and partial copy DNA (cDNA) sequence analysis.
  • ⁇ -Ag associated RNA is the product of a HBV variant, because no cross hybridization took place with southern and northern blots containing HBV DNA from the serum of a chimpanzee during HBsAg antigenemia.
  • ⁇ -Ag associated RNA is a unique component of the host, which is artificially coated with ⁇ -Ag and encapsulated by HBsAg, and this because no hybridization took place with either chromosomal DNA or total liver RNA of the same chimpanzee prior to HBsAg antigenemia.
  • ⁇ agent is a negative strand virus in which an RNA complementary to the ⁇ -RNA will encode ⁇ -Ag.
  • the present invention provides a probe that can be used for the clinical diagnosis of ⁇ infection and is free from the disadvantages inherent in immunological analyses referred to hereinbefore.
  • the invention provides a desoxyribonucleic acid (DNA) comprising DNA with at least 60% homology relative to a portion of ⁇ -ribonucleic acid ( ⁇ -RNA) and the capacity of selective hybridization with ⁇ -RNA.
  • DNA desoxyribonucleic acid
  • ⁇ -RNA ⁇ -ribonucleic acid
  • the invention provides such a DNA which additionally comprises vector DNA.
  • a suitable example is a plasmid composed of vector DNA and cDNA.
  • the invention comprises micro-organisms, such as Escherichia coli containing such a DNA.
  • the invention further provides a diagnostic agent for diagnosing ⁇ infection, comprising a DNA according to the invention provided with a detectable label.
  • detectable labels are known per se. Highly suitable is the radial label 32 P.
  • the invention finally comprises the use of a diagnostic agent according to the invention for diagnosing ⁇ infection.
  • a diagnostic agent according to the invention for diagnosing ⁇ infection.
  • use is made in a manner known per se of the capacities of selective hybridization of the labelled probe according to the invention with ⁇ --RNA.
  • FIG. 1 shows the base sequence of a portion of the partial ⁇ -cDNA.
  • FIG. 2 shows the codons and associated amino acids;
  • FIG. 3 shows the immunological, serological and biochemical events in a given champanzee after inoculation with the ⁇ agent.
  • Susceptible chimpanzees (Pan troglodytes) were infected with hepatitis B virus and the infections were followed by means of serological markers for HBsAg anti HBsAg, alanine amino transferase (ALT), aspertate amino transferase (AST), bilirubin, ⁇ -glutamate transpeptidase (GGTP).
  • serological markers for HBsAg anti HBsAg alanine amino transferase (ALT), aspertate amino transferase (AST), bilirubin, ⁇ -glutamate transpeptidase (GGTP).
  • ALT alanine amino transferase
  • AST aspertate amino transferase
  • GGTP ⁇ -glutamate transpeptidase
  • Nucleic acids derived from acute-phase serum particles and precipitated with ethanol were used directly for cDNA synthesis by the procedure described by Ohno et al. in Nucl.Acids Res.11, 6185-6202 (1983), except that the samples were previously heated in water at 70° C. for 5 minutes and cooled in solid carbon dioxide-ethanol.
  • AMV reverse transcriptase DNA complementary to the ⁇ antigen associated RNA was then synthesized as described by Efstratiados et al. in Cell 7, 279-288 (1976), except that no exogenous primer was added.
  • the single-stranded cDNA was used as a primer-template for the synthesis of the second strand by means of the Klenow fragment of DNA polymerase.
  • E.coli transformants containing sequences of the ⁇ antigen associated RNA were screened by in situ colony hybridization according to Grunstein et al. Proc.Natl.Acad.Sci.USA 72, 3961-3965 (1975), using RNA derived from either acute phase serum particles or control liver as a probe.
  • 32 P-RNA fragments were prepared by partial hydrolysis of the RNA in 25 mM glycine-NaOH, pH 9.0, 5 mM MgCl 2 at 37° C. for 3 hours (see the above publication by Ohno et al.) and subsequent labelling with ⁇ - 32 P/ATP and T 4 polynucleotide kinase. After incubation at 37° C. for 30 minutes the labeled RNA fragments were extracted with phenol/chloroform and precipitated with ethanol. Hybridization in 50% formamide and washing were performed as described in the above publication by Dijkema et al.
  • DNA/RNA samples were fractionated by electrophoresis under non-denaturing or denaturing (formaldehyde) conditions in 0.6-1.5% agarose gels. Fractionated samples were transferred to either Schleicher and Schull (BA 85) or Gene Screen nitrocellulose filters for non-denaturing and denaturing gels, respectively. Condition for hybridization and washing were in conformity with suppliers' specification.
  • DNA sequencing was performed as described by Maxam et al., Proc.Natl.Acad.Sci.USA 74, 560-564 (1977).
  • FIG. 3 shows the immunological, serological and biochemical events occurring in one of the chimpanzees (no.15) after inoculation with the ⁇ agent.
  • the presence (+) or absence (-) of HBV DNA and ⁇ -antigen associated RNA, as assayed by agarose gel electrophoresis is indicated at the top.
  • the middle part of the figure shows in diagrammatic form the presence of the serological markers ALT (black triangles), AST (white triangles), bilirubin (white circles) and GGTP (white squares).
  • the bottom part of the figure shows, in diagrammatic form, the titer of the serum HBsAg (black circles) and the anti-HBsAg (white circles), expressed as the ratio of positive to negative (P/N).
  • the animal At the time of superinfection with the ⁇ agent, the animal exhibited antigenemia due to HBsAg, as shown by circulating HBsAg and HBV DNA. Superinfection resulted in a transient antigenemia, marked by elevated ALT-AST levels 3 weeks after inoculation. Although during this period the amount of circulating HBsAg remained virtually constant, the HBV DNA level had become markedly lower 2 weeks after inoculation. ⁇ -antigen associated RNA was detected as early as 2 weeks after inoculation and reached an optimum after 3 weeks, which coincided with the ALT-AST markers. After 4 weeks no ⁇ -antigen associated RNA could be detected any longer, and the animal sera converted to anti-HBsAg 7 weeks after inoculation.
  • RNA associated with ⁇ -antigen revealed a single stranded linear nature
  • We were, however, unable to show the presence of a poly(A)tail either by binding the RNA to oligo (dT)cellulose columns or by priming the cDNA synthesis with oligo (dT) 12-18. Since, under native conditions, the RNA will form a structure with high internal base pairing it was assumed that the existing free 3'-end might serve as a primer for the synthesis of its own cDNA.
  • the cDNA prepared in this manner was cloned by standard techniques and amplified by the propagation of hybrid vectors in E.coli.
  • RNA samples were screened by differential hybridization with 32 P-labelled RNA derived from either acute phase serum or control liver. One transformant only gave a positive reaction with the RNA probe from the acute phase serum. This clone, designated p ⁇ -1 was subsequently used as a probe to screen a Northern blot of fractionated RNA samples isolated throughout the acute phase of antigenemia in chimpanzee no. 15. It was found that hybridization only occurred with samples previously shown to contain ⁇ -antigen associated RNA, and the position of migration coincided with the estimated (single) stranded length of 1750 nucleotides. No hybridization was observed with total liver RNA, chromosomal DNA extracted prior to HBsAg antigenemia, or total serum DNA extracted during HBsAg antigenemia of chimpanzee no. 15, in Northern and Southern blots.
  • p ⁇ -1 was digested with the restriction enzyme BglII (having only one cutting position in the ⁇ -cDNA part of p ⁇ -1) and the corresponding ends were labelled with ⁇ - 32 p ATP and T4 polynucleotide kinase.
  • the labelled hybrid vector was then digested with either the restriction enzyme AvaI or the restriction enzyme TaqI, and the labelled fragments were separated on a 5% polyacrylamide gel, isolated, and used for hybridization with RNA samples isolated from the acute phase serum of chimpanzee no. 15. It was found that only the BglII-AvaI probe showed a positive hybridization with the ⁇ -Ag associated RNA, which showed that its complementary strand was equivalent to the RNA.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

This invention relates to DNA having at least 60% homology relative to γ-RNA or a portion thereof and the capacity of selective hybridization with δ-RNA. Such DNA, if provided with a detectable label, such as 32 P can be used as a diagnostic agent to diagnose δ infection.

Description

The delta (δ) agent is a transmissible human pathogen that superinfects individuals having type B viral hepatitis in either the acute phase or the chronic carrier state. Since its discovery by Rizetto et al, Gut 18,997-1003 (1977) no certainty as to its identity has been obtained.
The hypothesis that the δ agent is a variant of the hepatitis B virus (HBV) should apparently be rejected on the basis of extensive transmission studies in the chimpanzee of selected inocula which do contain transmissible HBV but give no δ infection. The hypothesis that the δ agent is a non-defective infectious virus differing from HBV must be rejected on the ground of the finding that δ infection requires the presence of HBV (HBSAG) surface antigen. Epidemiological data in humans and transmission studies in chimpanzees have established the helper function of HBV in δ infection. Using immuno fluorescence, the δ-antigen/antisystem has been detected and identified, revealing no immunologic relationship to the known antigen/antibody (AG/AB) systems of HBV (i.e., surface(s), core(c) and envelope(e) antigen, respectively). In experimental infection in chimpanzees, however, the presence of δ-AG was found to be always associated with a discrete sub-population of HBsAg particles. These particles measure 35 to 37 nm in size and are composed of the δ Ag and an associated low-molecular RNA encapsulated by HBsAg. Although the particles per se are not unique for δ infection, the presence of the -Ag-associated small RNA could only be observed in serum taken during the acute phase of infection, both in man and in the chimpanzee. The amount of RNA was found to be proportionate to the relative δ-Ag concentration in the serum, while a specific immuno precipitation with anti-HBsAg was found to be possible.
The supposed helper functions of HBV in δ infection (i.e., replication and encapsulation) and the small size of the RNA have led to the hypothesis that the agent is a unique defective agent, which, for its reproduction, needs one or more HBV helper functions (for replication and expression) and that the δ RNA with its subviral size only encodes the genetic information for the δ antigen. The suppression of circulating HBV markers (HBV/DNA) observed during the superinfection of HBV-infected chimpanzees with the δ agent suggests that the agent disturbs the replication of the helper HBV. The encapsulation of the δ agent with HBsAg may be a different HBV helper function owing to which the agent can approach susceptible hepatocytes.
Starting from this hypothesis it has been endeavoured, and successfully so, to provide, by means of recombinant DNA technology, applied to the δ-antigen associated RNA, a new diagnostic agent for δ antigenemia, i.e. the presence of δ antigen in, for example, blood, at the RNA/DNA level, which avoids the disadvantages of existing immunological analysis for δ-antigen i.e. the disturbance of the existing solid-phase radio-immunoanalysis owing to the presence of high antititers. The preparatory work comprised the isolation of the δ-Ag associated RNA from acute-phase serum of experimentally infected chimpanzees, molecular cloning and partial copy DNA (cDNA) sequence analysis. Structural analysis by means of electron microscopy and determining the size of the RNA by means of agarose gel electrophoresis (approx. 5×105 dalton) led to the conclusion that the δ-RNA is a linear single strand molecule which upon renaturation exhibits a strong degree of intramolecular base-pairing. By using this property it was possible to realize a molecular cloning of the δ-RNA, which was productive of a partial cDNA clone approx. onethird of the length of the total genome. By using this cDNA clone as a probe we were able to reject the hypothesis that the δ-Ag associated RNA is the product of a HBV variant, because no cross hybridization took place with southern and northern blots containing HBV DNA from the serum of a chimpanzee during HBsAg antigenemia. We were also able to reject the hypothesis that the δ-Ag associated RNA is a unique component of the host, which is artificially coated with δ-Ag and encapsulated by HBsAg, and this because no hybridization took place with either chromosomal DNA or total liver RNA of the same chimpanzee prior to HBsAg antigenemia. Nucleotide sequence analysis of the resulting partial cDNA, and hybridization experiments with δ-RNA and strand-specific DNA probes, when it was found that only the probe carrying the hypothetical open reading frame for protein biosynthesis showed hybridization, led to the ultimate conclusion that the δ agent is a negative strand virus in which an RNA complementary to the δ-RNA will encode δ-Ag.
Thus the present invention provides a probe that can be used for the clinical diagnosis of δ infection and is free from the disadvantages inherent in immunological analyses referred to hereinbefore.
For this purpose the invention provides a desoxyribonucleic acid (DNA) comprising DNA with at least 60% homology relative to a portion of δ-ribonucleic acid (δ-RNA) and the capacity of selective hybridization with δ-RNA.
In a specific embodiment the invention provides such a DNA which additionally comprises vector DNA. A suitable example is a plasmid composed of vector DNA and cDNA. The invention comprises micro-organisms, such as Escherichia coli containing such a DNA.
The invention further provides a diagnostic agent for diagnosing δ infection, comprising a DNA according to the invention provided with a detectable label. Such detectable labels are known per se. Highly suitable is the radial label 32 P.
The invention finally comprises the use of a diagnostic agent according to the invention for diagnosing δ infection. In it, use is made in a manner known per se of the capacities of selective hybridization of the labelled probe according to the invention with δ--RNA.
The invention will be illustrated in and by the following experimental section. The accompanying FIG. 1 shows the base sequence of a portion of the partial δ-cDNA. FIG. 2 shows the codons and associated amino acids; FIG. 3 shows the immunological, serological and biochemical events in a given champanzee after inoculation with the δ agent.
Source of the antigen associated RNA
Susceptible chimpanzees (Pan troglodytes) were infected with hepatitis B virus and the infections were followed by means of serological markers for HBsAg anti HBsAg, alanine amino transferase (ALT), aspertate amino transferase (AST), bilirubin, δ-glutamate transpeptidase (GGTP). During the accute phase of H(V infection, as determined by the serological markers and HBV DNA the animals were superinfected by the intravenous administration of δ agent derived from the acute-phase serum of a chronic HBsAg-carrier chimpanzee showing intrahepatic and circulating δ-antigen.
Isolation of nucleic acids
Serial samples from chimpanzees infected with δ agent were analysed for the δ-antigen associated RNA by layering each serum sample onto a 4 ml. cushion of 20% (w/w) sucrose in 0.01 M phosphate pH 7.9/0.85% NaCl and ultracentrifugation at 200,000 xg at 4° C. for 5 hours in a Beckman SW 41 rotor as described by Rizetto et al., Proc.Natl.Acad.Sci. USA 77,6124-6128 (1980). particles were extracted for nucleic acid content by resuspension in 0.2 M NaCl/0.01 M sodium EDTA/2% Na Dod SO4 /0.05 M Tris-HCl, pH 8.0/1 mg/ml proteinase K (Sigma) and incubation for 1-2 hours at 37° C. After extraction with equal volumes of phenol and chloroform the aqueous phase was precipitated with ethanol. Further investigation comprised the use of electron microscopy and gel electrophoresis in which nucleic acids were analysed by 0.6-1.5% horizontal agarose gel electrophoresis under both native and denaturing conditions.
Molecular cloning of cDNA
Nucleic acids derived from acute-phase serum particles and precipitated with ethanol were used directly for cDNA synthesis by the procedure described by Ohno et al. in Nucl.Acids Res.11, 6185-6202 (1983), except that the samples were previously heated in water at 70° C. for 5 minutes and cooled in solid carbon dioxide-ethanol. By means of AMV reverse transcriptase, DNA complementary to the δ antigen associated RNA was then synthesized as described by Efstratiados et al. in Cell 7, 279-288 (1976), except that no exogenous primer was added. The single-stranded cDNA was used as a primer-template for the synthesis of the second strand by means of the Klenow fragment of DNA polymerase. This was followed by S1 nuclease digestion, sizing of double-stranded cDNA, tailing of double-stranded cDNA/vector and transformation of competent E.coli as described by Dijkema et al. in Nucl.Acids Res. 12, 1227-1242 (1984).
Screening of recombinant clones
E.coli transformants containing sequences of the δ antigen associated RNA were screened by in situ colony hybridization according to Grunstein et al. Proc.Natl.Acad.Sci.USA 72, 3961-3965 (1975), using RNA derived from either acute phase serum particles or control liver as a probe. 32 P-RNA fragments were prepared by partial hydrolysis of the RNA in 25 mM glycine-NaOH, pH 9.0, 5 mM MgCl2 at 37° C. for 3 hours (see the above publication by Ohno et al.) and subsequent labelling with δ-32 P/ATP and T4 polynucleotide kinase. After incubation at 37° C. for 30 minutes the labeled RNA fragments were extracted with phenol/chloroform and precipitated with ethanol. Hybridization in 50% formamide and washing were performed as described in the above publication by Dijkema et al.
Southern and Northern blotting
DNA/RNA samples were fractionated by electrophoresis under non-denaturing or denaturing (formaldehyde) conditions in 0.6-1.5% agarose gels. Fractionated samples were transferred to either Schleicher and Schull (BA 85) or Gene Screen nitrocellulose filters for non-denaturing and denaturing gels, respectively. Condition for hybridization and washing were in conformity with suppliers' specification.
DNA sequencing was performed as described by Maxam et al., Proc.Natl.Acad.Sci.USA 74, 560-564 (1977).
Results Transmission of δ agent to susceptible chimpanzees.
FIG. 3 shows the immunological, serological and biochemical events occurring in one of the chimpanzees (no.15) after inoculation with the δ agent. The presence (+) or absence (-) of HBV DNA and δ-antigen associated RNA, as assayed by agarose gel electrophoresis is indicated at the top. The middle part of the figure shows in diagrammatic form the presence of the serological markers ALT (black triangles), AST (white triangles), bilirubin (white circles) and GGTP (white squares). The bottom part of the figure shows, in diagrammatic form, the titer of the serum HBsAg (black circles) and the anti-HBsAg (white circles), expressed as the ratio of positive to negative (P/N).
At the time of superinfection with the δ agent, the animal exhibited antigenemia due to HBsAg, as shown by circulating HBsAg and HBV DNA. Superinfection resulted in a transient antigenemia, marked by elevated ALT-AST levels 3 weeks after inoculation. Although during this period the amount of circulating HBsAg remained virtually constant, the HBV DNA level had become markedly lower 2 weeks after inoculation. δ-antigen associated RNA was detected as early as 2 weeks after inoculation and reached an optimum after 3 weeks, which coincided with the ALT-AST markers. After 4 weeks no δ-antigen associated RNA could be detected any longer, and the animal sera converted to anti-HBsAg 7 weeks after inoculation.
Molecular cloning
Because the structural analysis (electron microscopy) of the RNA associated with δ-antigen revealed a single stranded linear nature, we first investigated the presence of a poly(A)tail. We were, however, unable to show the presence of a poly(A)tail either by binding the RNA to oligo (dT)cellulose columns or by priming the cDNA synthesis with oligo (dT) 12-18. Since, under native conditions, the RNA will form a structure with high internal base pairing it was assumed that the existing free 3'-end might serve as a primer for the synthesis of its own cDNA. The cDNA prepared in this manner was cloned by standard techniques and amplified by the propagation of hybrid vectors in E.coli. Recombinant clones were screened by differential hybridization with 32 P-labelled RNA derived from either acute phase serum or control liver. One transformant only gave a positive reaction with the RNA probe from the acute phase serum. This clone, designated p δ-1 was subsequently used as a probe to screen a Northern blot of fractionated RNA samples isolated throughout the acute phase of antigenemia in chimpanzee no. 15. It was found that hybridization only occurred with samples previously shown to contain δ-antigen associated RNA, and the position of migration coincided with the estimated (single) stranded length of 1750 nucleotides. No hybridization was observed with total liver RNA, chromosomal DNA extracted prior to HBsAg antigenemia, or total serum DNA extracted during HBsAg antigenemia of chimpanzee no. 15, in Northern and Southern blots.
Nucleotide sequence of p δ-1
As we had used the technique of dG/dC tailing, applied to pBR322 and δ-cDNA cleaved with the restriction enzyme PstI, we were able to remove the inserted fragment again by incubation with PstI. The insert length of p δ-1 was estimated to be 520 base pairs. Its nucleotide sequence was partly determined and is shown in FIG. 1. The 3 possible frames have been investigated for the occurrence of translation termination codons (TAA, TGA and TAG). Only one frame showed a stretch of appreciable length before a stop codon (TGA) appeared 70 base pairs before the end of the cDNA. The translation product of part of this hypothetical gene is shown in FIG. 2.
Strand specificity of δ-antigen associated RNA
In order to identify which strand of p δ-1 was equivalent to the δ-antigen associated RNA to strand-specific DNA probes were made. For this purpose p δ-1 was digested with the restriction enzyme BglII (having only one cutting position in the δ-cDNA part of p δ-1) and the corresponding ends were labelled with γ-32 p ATP and T4 polynucleotide kinase. The labelled hybrid vector was then digested with either the restriction enzyme AvaI or the restriction enzyme TaqI, and the labelled fragments were separated on a 5% polyacrylamide gel, isolated, and used for hybridization with RNA samples isolated from the acute phase serum of chimpanzee no. 15. It was found that only the BglII-AvaI probe showed a positive hybridization with the δ-Ag associated RNA, which showed that its complementary strand was equivalent to the RNA.
On Jan. 6, 1986 a strain of E.coli JA 221 (p δ-1), containing the plasmid p δ-1, was deposited with the Centraal Bureau voor Schimmelcultures (CBS) at Baarn, the Netherlands, under no. CBS 101.86.
Practical application
1-2 ml of the serum of 6 patients, whom we did not know to have a δ agent infection, was processed for an RNA isolation according to the procedure described above under 'Isolation of nucleic acids'. After hybridization of the radio-activated δ sequence with the RNA preparations, it was shown that in 3 of the 6 patients particles were present in the serum. This result corresponded to the results obtained by using an immunological analysis for the presence of δ antigen.

Claims (9)

I claim:
1. The DNA having at least 60% homology relative to a portion of δ-RNA and being capable of selective hybridization with δ-RNA.
2. The DNA as claimed in claim 1, comprising copy DNA of a portion of the δ-RNA, said copy DNA being capable of selective hybridization with δ-RNA.
3. A diagnostic agent for diagnosing δ infection, comprising DNA as claimed in any one of claims 1 and 2, provided with a detectable label.
4. A diagnostic agent as claimed in claim 3, in which the DNA is provided with the radio label 32 p.
5. Recombinant DNA containing vector DNA and an insertion therein of DNA of claim 1, having at least 60% homology relative to a portion of δ-RNA and being capable of selective hybridization with δ-RNA.
6. Recombinant DNA as claimed in claim 5, containing copy DNA of a portion of the δ-RNA, said copy DNA being capable of selective hybridization with δ-RNA.
7. A DNA selected from the group consisting of DNA having the following base sequence
______________________________________                                    
5' →                                                               
10           20            30                                             
CCCCGTTGCT   TTCTTTACTT    TCCTCCTCGC                                     
GGGGCAACGA   AAGAAATGAA    AGGAGGAGCG                                     
40           50            60                                             
TTCGGTCTCC   CCCTACTCCT    AGCATCTCCT                                     
AAGCCAGAGG   GGGATGAGGA    TCGTAGAGGA                                     
70           80            90                                             
CCTATCGCTA   TGGTCTTACT    CCTACCGCTC                                     
GGATAGCGAT   ACCAGAATGA    GGATGGCGAG                                     
100          110           120                                            
GAAGCGCCTC   TTGTTCGCTG    AAGGGGTCCT                                     
CTTCGCGGAG   AACAAGCGAC    TTCCCCAGGA                                     
130          140           150                                            
CTGGAGGTGA   TTTCTCTGCT    CATCTCCGAG                                     
GACCTCCACT   AAAGAGACGA    GTAGAGGCTC                                     
160          170           180                                            
TGGATTCCTC   CCTCTGGGTG    CTACTCAACC                                     
ACCTAAGGAG   GGAGACCCAC    GATGAGTTGG                                     
190          200           210                                            
CTTCGGGCCG   GAGTGCTCTC    CAGATCTGGA                                     
GAAGCCCGGC   CTCACGAGAG    GTCTAGACCT                                     
220          230           240                                            
GGTTGGGCCC   CTCGGATCGG    GAGGCCCGCT                                     
CCAACCCGGG   GAGCCTAGCC    CTCCGGGCGA                                     
250          260           270                                            
CCTTTTTCTT   CCACCTTCCT    CTTTCCCCTT                                     
GGAAAAAGAA   GGTGGAAGGA    GAAAGGGGAA                                     
280          290           300                                            
CCAGAGATTC   TCCGGCGTTG    TGGGGATCTC                                     
GGTCTCTAAG   AGGCCGCAAC    ACCCCTATAG                                     
310          320           330                                            
GTCCGCTTCC   TGAGACCTCT    CTTTGCTTCT                                     
CAGGCGAAGG   ACTCTGGAGA    GAAACGAAGA                                     
340          350           360                                            
TGGGAGTAGT   TTCTCCGACG    TTCCAATGCT                                     
ACCCTCATCA   AAGAGGCTGC    AAGGTTACGA                                     
370          380           390                                            
CTTTACCGTG   ACATCCCCTC    TCGGGAGCTG                                     
GAAATGGCAC   TGTAGGGGAG    AGCCCTCGAC                                     
                         A                                                
                         T    ← 5',                                  
______________________________________
a DNA homologous therewith as to at least 60%, or a portion thereof, and capable of selective hybridization with δ-RNA.
8. The DNA as claimed in claim 2, selected from the group consisting of DNA having the following base sequence
______________________________________                                    
5' →                                                               
10           20            30                                             
CCCCGTTGCT   TTCTTTACTT    TCCTCCTCGC                                     
GGGGCAACGA   AAGAAATGAA    AGGAGGAGCG                                     
40           50            60                                             
TTCGGTCTCC   CCCTACTCCT    AGCATCTCCT                                     
AAGCCAGAGG   GGGATGAGGA    TCGTAGAGGA                                     
70           80            90                                             
CCTATCGCTA   TGGTCTTACT    CCTACCGCTC                                     
GGATAGCGAT   ACCAGAATGA    GGATGGCGAG                                     
100          110           120                                            
GAAGCGCCTC   TTGTTCGCTG    AAGGGGTCCT                                     
CTTCGCGGAG   AACAAGCGAC    TTCCCCAGGA                                     
130          140           150                                            
CTGGAGGTGA   TTTCTCTGCT    CATCTCCGAG                                     
GACCTCCACT   AAAGAGACGA    GTAGAGGCTC                                     
160          170           180                                            
TGGATTCCTC   CCTCTGGGTG    CTACTCAACC                                     
ACCTAAGGAG   GGAGACCCAC    GATGAGTTGG                                     
190          200           210                                            
CTTCGGGCCG   GAGTGCTCTC    CAGATCTGGA                                     
GAAGCCCGGC   CTCACGAGAG    GTCTAGACCT                                     
220          230           240                                            
GGTTGGGCCC   CTCGGATCGG    GAGGCCCGCT                                     
CCAACCCGGG   GAGCCTAGCC    CTCCGGGCGA                                     
250          260           270                                            
CCTTTTTCTT   CCACCTTCCT    CTTTCCCCTT                                     
GGAAAAAGAA   GGTGGAAGGA    GAAAGGGGAA                                     
280          290           300                                            
CCAGAGATTC   TCCGGCGTTG    TGGGGATCTC                                     
GGTCTCTAAG   AGGCCGCAAC    ACCCCTATAG                                     
310          320           330                                            
GTCCGCTTCC   TGAGACCTCT    CTTTGCTTCT                                     
CAGGCGAAGG   ACTCTGGAGA    GAAACGAAGA                                     
340          350           360                                            
TGGGAGTAGT   TTCTCCGACG    TTCCAATGCT                                     
ACCCTCATCA   AAGAGGCTGC    AAGGTTACGA                                     
370          380           390                                            
CTTTACCGTG   ACATCCCCTC    TCGGGAGCTG                                     
GAAATGGCAC   TGTAGGGGAG    AGCCCTCGAC                                     
                         A                                                
                         T    ← 5',                                  
______________________________________
a DNA homologous therewith as to at least 60%, or a portion thereof, and capable of selective hybridization with δ-RNA.
9. Recombinant DNA selected from the group consisting of DNA having the following base sequence
______________________________________                                    
5' →                                                               
10           20            30                                             
CCCCGTTGCT   TTCTTTACTT    TCCTCCTCGC                                     
GGGGCAACGA   AAGAAATGAA    AGGAGGAGCG                                     
40           50            60                                             
TTCGGTCTCC   CCCTACTCCT    AGCATCTCCT                                     
AAGCCAGAGG   GGGATGAGGA    TCGTAGAGGA                                     
70           80            90                                             
CCTATCGCTA   TGGTCTTACT    CCTACCGCTC                                     
GGATAGCGAT   ACCAGAATGA    GGATGGCGAG                                     
100          110           120                                            
GAAGCGCCTC   TTGTTCGCTG    AAGGGGTCCT                                     
CTTCGCGGAG   AACAAGCGAC    TTCCCCAGGA                                     
130          140           150                                            
CTGGAGGTGA   TTTCTCTGCT    CATCTCCGAG                                     
GACCTCCACT   AAAGAGACGA    GTAGAGGCTC                                     
160          170           180                                            
TGGATTCCTC   CCTCTGGGTG    CTACTCAACC                                     
ACCTAAGGAG   GGAGACCCAC    GATGAGTTGG                                     
190          200           210                                            
CTTCGGGCCG   GAGTGCTCTC    CAGATCTGGA                                     
GAAGCCCGGC   CTCACGAGAG    GTCTAGACCT                                     
220          230           240                                            
GGTTGGGCCC   CTCGGATCGG    GAGGCCCGCT                                     
CCAACCCGGG   GAGCCTAGCC    CTCCGGGCGA                                     
250          260           270                                            
CCTTTTTCTT   CCACCTTCCT    CTTTCCCCTT                                     
GGAAAAAGAA   GGTGGAAGGA    GAAAGGGGAA                                     
280          290           300                                            
CCAGAGATTC   TCCGGCGTTG    TGGGGATCTC                                     
GGTCTCTAAG   AGGCCGCAAC    ACCCCTATAG                                     
310          320           330                                            
GTCCGCTTCC   TGAGACCTCT    CTTTGCTTCT                                     
CAGGCGAAGG   ACTCTGGAGA    GAAACGAAGA                                     
340          350           360                                            
TGGGAGTAGT   TTCTCCGACG    TTCCAATGCT                                     
ACCCTCATCA   AAGAGGCTGC    AAGGTTACGA                                     
370          380           390                                            
CTTTACCGTG   ACATCCCCTC    TCGGGAGCTG                                     
GAAATGGCAC   TGTAGGGGAG    AGCCCTCGAC                                     
                         A                                                
                         T    ← 5',                                  
______________________________________
a DNA homologous therewith as to at least 60%, or a portion thereof, and capable of selective hybridization with δ-RNA.
US06/823,196 1984-07-31 1986-01-28 Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof Expired - Lifetime US4959462A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8402392 1984-07-31
NL8402392A NL192267C (en) 1984-07-31 1984-07-31 Deoxyribonucleic acid, microorganism, diagnostic tool for diagnosing HDV infection and its use.

Publications (1)

Publication Number Publication Date
US4959462A true US4959462A (en) 1990-09-25

Family

ID=19844287

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/823,196 Expired - Lifetime US4959462A (en) 1984-07-31 1986-01-28 Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof

Country Status (4)

Country Link
US (1) US4959462A (en)
EP (1) EP0234050B1 (en)
JP (1) JPH0824581B2 (en)
NL (1) NL192267C (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378814A (en) * 1986-06-17 1995-01-03 Chiron Corporation Hepatitis delta viral polypeptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0131974A1 (en) * 1983-06-08 1985-01-23 Akzo N.V. Determination of delta-antigens in body fluids
EP0174669A2 (en) * 1981-03-28 1986-03-19 Von der Helm, Klaus Process for the production of a hybrid DNA containing the complementary hepatitis A virus genome, this hybrid DNA and plasmid vector containing it, virus-specific proteins expressed by this hybrid DNA, vaccines containing and produced from these proteins
US4619896A (en) * 1983-03-04 1986-10-28 Shattock Alan G Process for obtaining delta antigen of hepatitis D virus and use of said antigen as a diagnostic agent
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4952561A (en) * 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0174669A2 (en) * 1981-03-28 1986-03-19 Von der Helm, Klaus Process for the production of a hybrid DNA containing the complementary hepatitis A virus genome, this hybrid DNA and plasmid vector containing it, virus-specific proteins expressed by this hybrid DNA, vaccines containing and produced from these proteins
US4711955A (en) * 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4619896A (en) * 1983-03-04 1986-10-28 Shattock Alan G Process for obtaining delta antigen of hepatitis D virus and use of said antigen as a diagnostic agent
EP0131974A1 (en) * 1983-06-08 1985-01-23 Akzo N.V. Determination of delta-antigens in body fluids

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Chemical Abstracts, vol. 100, No. 17, 23rd Apr. 1984, p. 481, col. 2, Abstract No. 137082f, Columbus, Ohio, U.S.; F. Bonino et al.: "Delta Hepatitis Agent: Structural and Antigenic Properties of the Delta Associated Particle"; & Infect. Immun., vol. 43, No. 3, 1984, pp. 1000-1005.
Chemical Abstracts, vol. 100, No. 17, 23rd Apr. 1984, p. 481, col. 2, Abstract No. 137082f, Columbus, Ohio, U.S.; F. Bonino et al.: Delta Hepatitis Agent: Structural and Antigenic Properties of the Delta Associated Particle ; & Infect. Immun. , vol. 43, No. 3, 1984, pp. 1000 1005. *
Chemical Abstracts, vol. 100, No. 21, 21st May 1984, p. 328, col. 1, Abstract No. 171214k, Columbus, Ohio, U.S.; B. Hoyer et al.: "Properties of Delta-Associated Ribonucleic Acid"; & Prog. Clin. Biot. Res., vol. 143, 1983, pp. 92-97.
Chemical Abstracts, vol. 100, No. 21, 21st May 1984, p. 328, col. 1, Abstract No. 171214k, Columbus, Ohio, U.S.; B. Hoyer et al.: Properties of Delta Associated Ribonucleic Acid ; & Prog. Clin. Biot. Res., vol. 143, 1983, pp. 92 97. *
Chemical Abstracts, vol. 104, No. 21, 26th May 1986, p. 326, cols. 1, 2, Abstract No. 182922y, Columbus, Ohio, U.S., Ne. Cen. Org. voor Toegepast Natuurwetenschappelijk Onderzoek; Deoxyribonucleic Acid, Microorganisms, Diagnositc Means for Delta Infection, and Use There Of ; N.A. 8402392 published 17th Feb. 1986, priority 31st Jul. 1984. *
Chemical Abstracts, vol. 104, No. 21, 26th May 1986, p. 326, cols. 1, 2, Abstract No. 182922y, Columbus, Ohio, U.S., Ne. Cen. Org. voor Toegepast-Natuurwetenschappelijk Onderzoek; "Deoxyribonucleic Acid, Microorganisms, Diagnositc Means for Delta Infection, and Use There Of"; N.A. 8402392 published 17th Feb. 1986, priority 31st Jul. 1984.
Chemical Abstracts, vol. 105, No. 1, 7th Jul. 1986, p. 149, col. 2, Abstract No. 1518y, Columbus, Ohio, U.S.: K. J. Denniston et al.: "Cloned Fragment of the Hepatitis Delta Virus RNA Genome: Sequence and Diagnostic Application"; & Science vol. 232, 1986, pp. 873-875.
Chemical Abstracts, vol. 105, No. 1, 7th Jul. 1986, p. 149, col. 2, Abstract No. 1518y, Columbus, Ohio, U.S.: K. J. Denniston et al.: Cloned Fragment of the Hepatitis Delta Virus RNA Genome: Sequence and Diagnostic Application ; & Science vol. 232, 1986, pp. 873 875. *
Denniston et al, The Chemical Abstracts 105:1518y (1986). *
Richman, D. D. et al. (1984), J. of Infectious Diseases, 149(3), pp. 298 310. *
Richman, D. D. et al. (1984), J. of Infectious Diseases, 149(3), pp. 298-310.
Tiollais, P. et al. (1985), Nature, 317, pp. 489 495. *
Tiollais, P. et al. (1985), Nature, 317, pp. 489-495.
Wang et al, Nature, 323, 508 514 (1986). *
Wang et al, Nature, 323, 508-514 (1986).

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378814A (en) * 1986-06-17 1995-01-03 Chiron Corporation Hepatitis delta viral polypeptides
US5389528A (en) * 1986-06-17 1995-02-14 Chiron Corporation Hepatitis δ diagnostics and vaccines
US5747044A (en) * 1986-06-17 1998-05-05 Chiron Corporation Hepatitis delta diagnostics and vaccines
US5750350A (en) * 1986-06-17 1998-05-12 Chiron Corporation Hepatitis δ diagnostics
US5932219A (en) * 1986-06-17 1999-08-03 Chiron Corporation Hepatitis delta virus p27.sup.δ and p24.sup.δ vaccine

Also Published As

Publication number Publication date
EP0234050B1 (en) 1991-03-27
NL192267B (en) 1996-12-02
EP0234050A1 (en) 1987-09-02
NL8402392A (en) 1986-02-17
NL192267C (en) 1997-04-03
JPS62179389A (en) 1987-08-06
JPH0824581B2 (en) 1996-03-13

Similar Documents

Publication Publication Date Title
Delius et al. Structure of the hepatitis B virus genome
Sharp et al. Mapping of adenovirus 2 RNA sequences in lytically infected cells and transformed cell lines
CA1258623A (en) Probe containing a modified nucleic acid, recognizable by specific antibodies and use of this probe and these specific antibodies to detect and characterize a homologous dna sequence
EP0013828B2 (en) Recombinant DNA, hosts transformed with it and processes for the preparation of polypeptides
US5591638A (en) Method for the transformation of cells, particularly eukaryotes by a DNA originating from viruses of hepatitis, more particularly from virus of B viral hepatitis, and preparations containing the expression products of said DNAs
Tibbetts Physical organization of subgroup B human adenovirus genomes
Ruiz-Opazo et al. Evidence for supercoiled hepatitis B virus DNA in chimpanzee liver and serum Dane particles: possible implications in persistent HBV infection
Leis et al. Rous sarcoma virus p19 binds to specific double-stranded regions of viral RNA: effect of p19 on cleavage of viral RNA by RNase III
US5024938A (en) Recombinant DNA inserted with hepatitis B virus gene, mammalian cells transformed with cloned viral DNA, and production of hepatitis B virus proteins
GB2034323A (en) Production of DNA Comprising B Hepatitis Viral Genome
AU619170B2 (en) Diagnostic assays using nucleic acid probes
Menissier et al. Free cauliflower mosaic virus supercoiled DNA in infected plants
Field et al. There are at least two yeast viral double-stranded RNAs of the same size: an explanation for viral exclusion
EP0182442B1 (en) Recombinant dna molecules and their method of production
Lasfargues et al. A human breast tumor cell line (BT-474) that supports mouse mammary tumor virus replication
Siddiqui et al. Ground squirrel hepatitis virus DNA: molecular cloning and comparison with hepatitis B virus DNA
Chow et al. Identification and characterization of a protein covalently bound to DNA of minute virus of mice
WO2003083094A1 (en) Hbv drug resistance drug resistance detection methods
US4959462A (en) Desoxyribonucleic acid; microorganisms; diagnostic agent for delta infection and the use thereof
Pagratis et al. Detection of bacteriophage φ6 minus-strand rna and novel rnrna isoconformers synthesized in vivo and in vitro, by strand-separating agarose gels
Ward et al. Reovirus-specific ribonucleic acid from polysomes of infected L cells
Humphries et al. Differences between the endogenous and exogenous DNA sequences of Rous-associated virus-O
JPH0543352B2 (en)
EP0218474A2 (en) Novel DNA and polypeptide
Konings et al. Synthesis of Bacteriophage M13-Specific Proteins in a DNA-Dependent Cell-Free System II. In Vitro Synthesis of Biologically Active Gene 5 Protein

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEDERLANDSE CENTRALE ORGANISATIE VOOR TOEGEPAST-NA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:DIJKEMA, REINDER;KOS, ANTONIDES;REEL/FRAME:004526/0905

Effective date: 19860127

STCF Information on status: patent grant

Free format text: PATENTED CASE

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment
FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 12